: Bavarian Nordic shares jump after reaching monkeypox vaccine deal extension with Canada


Shares of BAVA, +6.37% jumped 11% as the drugmaker said it signed a contract amendment with Public Health Canada that’s valued at up to $434 million over ten years. Under the new contract amendment, the majority of the confirmed order for Imvamune will be delivered in 2023, Bavarian Nordic said. Imavune, known as Jynneos in the U.S., is the only smallpox vaccine authorized for use against monkeypox.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Starbucks investors push for review of how company is dealing with union activity
Next articleDow industrials down 200 points early Monday as investors await Fed decision


Please enter your comment!
Please enter your name here